JAZZ250117P160000
- 0.00
- 0.000.00%
Jazz Pharmaceuticals Newsroom
Jefferies Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $170
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Natera (NTRA) and Neumora Therapeutics, Inc. (NMRA)
Needham Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Cuts Target Price to $195
TD Cowen Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $195
Jazz Pharmaceuticals (JAZZ) Gets a Buy From TD Cowen
Analysts Conflicted on These Healthcare Names: Jazz Pharmaceuticals (JAZZ), Acadia Healthcare (ACHC) and Genmab (GMAB)
Truist Financial Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating
A Quick Look at Today's Ratings for Jazz Pharmaceuticals(JAZZ.US), With a Forecast Between $163 to $230
Morgan Stanley Upgrades Jazz Pharmaceuticals to Overweight From Equalweight, $175 Price Target
RBC Capital Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $179
Piper Sandler Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $163
Piper Sandler Sticks to Their Buy Rating for Jazz Pharmaceuticals (JAZZ)
Needham Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $207
RBC Capital Reiterates Outperform on Jazz Pharmaceuticals, Maintains $179 Price Target
Jazz Pharmaceuticals Analyst Ratings
RBC Capital Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $179
RBC Capital Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
A Quick Look at Today's Ratings for Jazz Pharmaceuticals(JAZZ.US), With a Forecast Between $160 to $207
Barclays Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Jazz Pharmaceuticals Analyst Ratings